INDUSTRY MEMBER: Arvinas, Inc.

At Arvinas, we are committed to improving the lives of people living with serious disease, including breast cancer. Through our innovative PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, we are pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs and is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.